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Nussenzweig and colleagues evaluate genomic instability and germinal center derived lymphoma-
genesis in mice infected with Plasmodium to recreate some of the hallmark characteristics of
Burkitt lymphoma, a form of cancer more common in parts of Africa where malaria is endemic.The DNA mutator activation-induced
cytosine deaminase (AID) is critical for
antibody affinity maturation by creating
nicks and double strand breaks (DSBs)
during the processes of class switch
recombination (CSR) and somatic hyper-
mutation. However, problems arise when
this activity becomes promiscuous, tar-
geting non-immunoglobulin gene (non-
Ig) locations in the B cell genome (Liu
and Schatz, 2009). These non-Ig muta-
tions can lead to the ligation of inap-
propriate segments of chromosomes,
causing expression of oncogenes or
repression of tumor-suppressors, ulti-
mately leading to fatal malignancies (sum-
marized in Robbiani and Nussenzweig,
2013) Most studies correlating AID’s
DNA mutator activity with chromosomal
translocations have been performed with
artificial systems of AID misregulation or
via immune responses elicited by experi-
mental means in the laboratory. Thus, an
experimental system for B cell induction
in a pathologically relevant infectious dis-
ease model has been lacking. In the Rob-
biani et al. (2015) paper published in this
issue ofCell, the laboratory ofMichel Nus-
senzweig has linked B cell genome muta-
genesis by AID to the real world problem
of Plasmodium infection and its connec-
tion with endemic Burkitt lymphoma in
equatorial Africa and New Guinea.
Burkitt lymphoma is an aggressive non-
Hodgkin lymphoma, first described in
detail by Denis Burkitt in 1958 at the
Mulago hospital in Uganda. It is a B cell
malignancy occurring most frequently in
children in areas with endemic malaria,
and with lower frequencies in all other
parts of the world. The connection be-
tween the level of malaria infection and
the number of cases is striking (Magrath,
2012). When malaria was successfully
eradicated from the Zanzibar islands offthe coast of Tanzania, Burkitt lymphoma
disappeared; when the eradication pro-
gram for malaria was halted, cases
reappeared. In areas of endemic malaria,
Burkitt lymphoma is characterized by tu-
mors affecting most frequently the jaw
and facial bones, while sporadic cases
(areas outside endemic malarial infection)
frequently present with tumors in the gut
and upper respiratory tract. Whether
endemic or sporadic, there is an almost
100% correlation between diagnosis and
a reciprocal chromosomal translocation
involving the proto-oncogene MYC on
chromosome 8 and one of the Ig gene
heavy or light chain loci on chromosomes
14, 2, or 22 (Boxer and Dang, 2001).
Infecting mice with Plasmodium cha-
baudi (a rodent-specific species that
may display characteristics distinct from
the human infectious agent Plasmodium
falciparum), Robbiani and colleagues
model endemic Burkitt lymphoma. To
summarize succinctly their findings, Plas-
modium infection induces a robust and
long-lasting expansion of germinal center
B cells, AID expression is restricted to
these cells and sustained at high levels
over a period of at least 10 weeks
following infection, and widespread chro-
mosomal translocations are found in
malaria-infected germinal center B cells
(schematized for potential human equiva-
lent in Figure 1). The latter finding is
observed through a sophisticated set of
experiments using the translocation cap-
ture-sequencing technique (Klein et al.,
2011). The authors experimentally link
the rapid onset of AID expression in
germinal center B cells to the spectrum
of translocation events and the type of
lymphomagenesis. Finally, they test the
role of AID and p53 in the development
of lymphomas in their malaria model in
which one infected cohort is wild-typeCell 16(expresses both p53 and AID), one lacks
p53 but has AID, and one lacks both p53
and AID. The first group develops no tu-
mors, the second group uniformly de-
velops lymphomas that are mostly mature
and consistent with germinal center origin
(a sign of AID-induced tumorigenesis),
and the final group develops mainly
benign splenomegaly (67%) with only a
small number of animals developing lym-
phomas. Basically, if mice are infected
with Plasmodium and are p53; AID+
they will develop lymphomas, but if they
are p53; AID lymphoma will develop in
rare cases but other malarial infection
phenotypes will occur as expected.
The widespread genomic instability in
these malaria germinal center B cells
can be localized to previously identified
regions of AID-dependent mutagenesis
as well as to regions prone to DNA
breakage referred to as early replication
fragile sites (Figure 1, right). Thus, it is
possible that germinal center B cells in
malaria may provide a patho-physiolog-
ical model for AID-independent DNA rear-
rangement in the context of a germinal
center reaction. The reader may wonder
how the malaria parasite targets the
germinal center. The Toll like receptors
(TLRs), found on mature B cells, are able
to activate AID. TLR agonists include
hemozoin, a byproduct of hemoglobin
digestion by Plasmodium, and CpG en-
riched DNA found in many microorgan-
isms (Magrath, 2012). Thus, Plasmodium
infection has the potential to engage path-
ways that directly activate AID in the
germinal center. Taken together, in the
context of distribution and mechanism of
translocations and pathways that activate
AID expression, there are numerous op-
portunities for exciting future studies.
However, it must be noted that the mice
of Robbiani et al. do not recapitulate the2, August 13, 2015 ª2015 Elsevier Inc. 697
Figure 1. From Mosquito to Lymphoma
Depicted is a schematic of Plasmodium infection leading to B cell genomic instability and AID-mediated IgH-myc translocation in humans, extrapolated from the
study of Robbiani et al. (2015). A female mosquito infects the human host, releasing the infective malarial sporozoite, which travels through the blood to the liver,
where it reproduces, infecting red blood cells and ultimately lysing them. Hemozoin, a product of the trophozoite feeding on (and lysing) red blood cells, activates
Toll-like receptors on the surface of lymphocytes found within the dark zone of the germinal center. Activation of the Toll-like receptor causes B cell hyperplasia
and activation of AID beyond AID’s normal roles in class switch recombination and somatic hypermutation, causing breakage and rejoining in sites previously
identified as AID targets as well as in locations within early replication fragile sites. The AID targets in Burkitt lymphoma involve rejoining of the heavy and light
chain loci in the immunoglobulin loci with the proto-oncogene c-myc.human features of the disease in every
detail (tumor location and histopathology
are different, for example.) This distinction
needs to be considered cautiously.
We have recently progressed in our
understanding of the various mechanisms
that can promote AID-induced chromo-
somal translocations. Specifically, anti-
sense transcription at divergently tran-
scribed enhancer sites and genic
transcription start sites sometimes over-
laps with translocations (Pefanis et al.,
2014; Pefanis et al., 2015), particularly in
the context of convergence of the RNA
pol II complex (Meng et al., 2014). More-
over, these AID-induced translocation
sites are enriched inside topologically
defined super-enhancer domains, them-
selves enriched in enhancer-promoter in-
teractions (Qian et al., 2014). The naturally
occurring question, then, is: do all these
chromosomal translocation mechanics
apply in malaria germinal center cells
and can we discover additional informa-698 Cell 162, August 13, 2015 ª2015 Elsevietion from this enticing system? How do
translocations occur at early replication
fragile sites, and what biological parame-
ters do they follow that prevents them
from causing robust tumorigenesis?
Indeed, Robbiani’s paper is a very inter-
esting study that raises many new ques-
tions and provides the B cell field an
opportunity to contribute further to the
understanding of pathological conditions
that are challenges in global healthcare.
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